Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses : EAACI task force on eicosanoids consensus report in times of COVID-19
(2022) In Allergy: European Journal of Allergy and Clinical Immunology 77(8). p.2337-2354- Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context,... (More)
Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.
(Less)
- author
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- asthma, biologicals, COVID-19, LTRA, NSAID
- in
- Allergy: European Journal of Allergy and Clinical Immunology
- volume
- 77
- issue
- 8
- pages
- 2337 - 2354
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:85125780339
- pmid:35174512
- ISSN
- 0105-4538
- DOI
- 10.1111/all.15258
- language
- English
- LU publication?
- no
- id
- 0b975048-cef0-4b62-8243-7da9f6a8a78a
- date added to LUP
- 2022-04-26 11:33:13
- date last changed
- 2024-06-13 12:07:28
@article{0b975048-cef0-4b62-8243-7da9f6a8a78a,
abstract = {{<p>Non-steroidal anti-inflammatory drugs (NSAIDs) and other eicosanoid pathway modifiers are among the most ubiquitously used medications in the general population. Their broad anti-inflammatory, antipyretic, and analgesic effects are applied against symptoms of respiratory infections, including SARS-CoV-2, as well as in other acute and chronic inflammatory diseases that often coexist with allergy and asthma. However, the current pandemic of COVID-19 also revealed the gaps in our understanding of their mechanism of action, selectivity, and interactions not only during viral infections and inflammation, but also in asthma exacerbations, uncontrolled allergic inflammation, and NSAIDs-exacerbated respiratory disease (NERD). In this context, the consensus report summarizes currently available knowledge, novel discoveries, and controversies regarding the use of NSAIDs in COVID-19, and the role of NSAIDs in asthma and viral asthma exacerbations. We also describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to predict responses to LTRA therapy and discuss a potential role of LTRA therapy in COVID-19 treatment. Moreover, we discuss interactions of novel T2 biologicals and other eicosanoid pathway modifiers on the horizon, such as prostaglandin D2 antagonists and cannabinoids, with eicosanoid pathways, in context of viral infections and exacerbations of asthma and allergic diseases. Finally, we identify and summarize the major knowledge gaps and unmet needs in current eicosanoid research.</p>}},
author = {{Sokolowska, Milena and Rovati, G. Enrico and Diamant, Zuzana and Untersmayr, Eva and Schwarze, Jürgen and Lukasik, Zuzanna and Sava, Florentina and Angelina, Alba and Palomares, Oscar and Akdis, Cezmi and O'Mahony, Liam and Jesenak, Milos and Pfaar, Oliver and Torres, María José and Sanak, Marek and Dahlén, Sven Erik and Woszczek, Grzegorz}},
issn = {{0105-4538}},
keywords = {{asthma; biologicals; COVID-19; LTRA; NSAID}},
language = {{eng}},
number = {{8}},
pages = {{2337--2354}},
publisher = {{Wiley-Blackwell}},
series = {{Allergy: European Journal of Allergy and Clinical Immunology}},
title = {{Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses : EAACI task force on eicosanoids consensus report in times of COVID-19}},
url = {{http://dx.doi.org/10.1111/all.15258}},
doi = {{10.1111/all.15258}},
volume = {{77}},
year = {{2022}},
}